Since we found the synergistic effect when neuroblastoma cells were treated with combination of YM155 with EZH2 inhibitors, we also tested other combinations of inhibitors against targets in the 27-gene signature (AURKA inhibitor MLN8237, MELK inhibitor OTS167, and TTK inhibitor AZ3146), in two different neuroblastoma cell lines BE2C (with MYCN amplification) and SKNSH (without MYCN amplification). The gene discussed is EZH2; the disease is neuroblastoma.